R&D
Successfully Completed Phase I Single Dose Study for GXV-001
2023/1/10
GEXVal Inc.January 10, 2023 GEXVal Inc. is conducting a Phase I study for GXV-001, a new drug candidate, throu […]
GEXVal Interviewed at World Fragile X Day
2022/8/10
GEXVal Inc.August 10, 2022 GEXVal announced today that Dr. Lili Mao, Director of the Clinical Development Unit […]
Phase I Clinical Trial of GXV-001 Initiated in Australia
2022/7/21
GEXVal Inc. is pleased to announce that we have officially initiated phase I clinical trial of its drug candid […]
HREC Approval of the Initiation of Phase 1 Study of GXV-001 in Australia
2022/6/10
GEXVal Inc.June 10, 2022 GEXVal Inc. has invited experienced doctors and specialists from Japan, Australia, Sw […]